Natera
NTRA | NASDAQ
$288.48
-$30.61 (-9.59%)
At close: Nov 16, 2026, 4:00 PM ET
$293.01
+$4.53 (+1.57%)
After-hours:
Nov 16, 2026, 7:56 PM ET
Natera Company Profile
Company profile explainedCompany Profile
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Key Executives
| Name | Position |
|---|---|
| Steven Leonard Chapman | Chief Executive Officer & Director |
| Daniel Rabinowitz | Secretary & Chief Legal Officer |
| Michael Brophy | Chief Financial Officer |
| Rishi Kacker | Chief Technology Officer |
| Eric A. Evans | Chief Scientific Officer |
| John Fesko | President & Chief Business Officer |
| Jonathan Sheena | Co-Founder & Director |
| Matthew Rabinowitz | Co-Founder & Executive Chairman |
| Olesya A. Anisimova | Chief Accounting Officer |
| Solomon Moshkevich | President of Clinical Diagnostics |
Natera
| Country | United States |
| IPO Date | Jul 1, 2015 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 6,138 |
| CEO | Steven Leonard Chapman |
Contact Details
13011 McCallen Pass Building A Austin,
Texas 78753 United States
Stock Details
| Ticker Symbol | NTRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001604821 |
| CUSIP Number | 632307104 |
| ISIN Number | US6323071042 |
| SIC Code | 8071 |
Recent News
- 1 day ago / marketbeat.comNatera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029
- 2 days ago / marketbeat.comNatera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”
- 5 days ago / seekingalpha.comNatera, Inc. (NTRA) Presents at 2026 UBS Global Healthcare Conference Transcript
- 5 days ago / seekingalpha.comNatera, Inc. (NTRA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
- 7 days ago / zacks.comNatera Q3 Earnings Call Highlights $6B Target & Raised 2026 Outlook
- 8 days ago / zacks.comNTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View Up
- 10 days ago / seekingalpha.comNatera, Inc. (NTRA) Q3 2026 Earnings Call Transcript
- 11 days ago / benzinga.comNatera Stock Plummets After Mixed Q3 Financials
- 11 days ago / marketbeat.comWhat Natera (NTRA) Said on Its Q3 Earnings Call
- 11 days ago / businesswire.comNatera Reports Third Quarter 2026 Financial Results
Add to Watchlist
Select watchlists to add or remove NTRA